Rafael Holdings Files 10-K/A Amendment

TL;DR

Rafael Holdings filed an amended 10-K for FY24, check for updates.

AI Summary

Rafael Holdings, Inc. filed an amendment (Amendment No. 2) to its annual report on Form 10-K for the fiscal year ended July 31, 2024. This filing, dated January 8, 2025, provides updated information for the company, which is incorporated in Delaware and has its principal executive offices in Newark, New Jersey.

Why It Matters

This amendment to the annual report provides updated financial and operational information for Rafael Holdings, Inc., which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is an amendment to a routine annual report and does not appear to contain significant new negative information.

Key Numbers

• 0731 — Fiscal Year End (Indicates the end of the reporting period for the annual report.)
• 20250108 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

• Rafael Holdings, Inc. (company) — Registrant
• July 31, 2024 (date) — Fiscal year end
• January 8, 2025 (date) — Filing date
• Delaware (location) — State of incorporation
• Newark, New Jersey (location) — Principal executive offices
• RFL (ticker) — Trading symbol

FAQ

Key Financial Figures

• $0.01 — stered Class B common stock, par value $0.01 per share RFL New York Stock Exchange
• $1.81 — quarter) of the Class B common stock of $1.81 per share, as reported on the New York
• $2.7 million — of July 31, 2024, we held approximately $2.7 million in cash and cash equivalents, approxima
• $63.3 million — ash and cash equivalents, approximately $63.3 million in short-term available-for-sale securi
• $0.4 million — ort-term available-for-sale securities, $0.4 million in third-party and related party receiv
• $0.5 million — elated party receivables, approximately $0.5 million in interests receivable, and $2.5 milli
• $2.5 million — .5 million in interests receivable, and $2.5 million in investment in hedge funds. Investmen

Filing Documents

• ea0227013-10ka2_rafael.htm (10-K/A) — 615KB
• ea022701301ex31-01_rafael.htm (EX-31.01) — 9KB
• ea022701301ex31-02_rafael.htm (EX-31.02) — 9KB
• ea022701301ex32-01_rafael.htm (EX-32.01) — 4KB
• ea022701301ex32-02_rafael.htm (EX-32.02) — 4KB
• 0001213900-25-001971.txt ( ) — 994KB
• rfl-20240731.xsd (EX-101.SCH) — 3KB
• rfl-20240731_def.xml (EX-101.DEF) — 17KB
• rfl-20240731_lab.xml (EX-101.LAB) — 34KB
• rfl-20240731_pre.xml (EX-101.PRE) — 18KB
• ea0227013-10ka2_rafael_htm.xml (XML) — 7KB

Signatures

Signatures 74 i This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that contain the words "believes," "anticipates," "expects," "plans," "intends" and similar words and phrases. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the results projected in any forward-looking statement. In addition to the factors specifically noted in the forward-looking statements, other important factors, risks and uncertainties that could result in those differences include, but are not limited to, those discussed under Item 1A to Part I "Risk Factors" in this Annual Report. The forward-looking statements are made as of the date of this Annual Report, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth in this report and the other information set forth from time to time in our reports filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933 and the Securities Exchange Act of 1934, including our reports on Forms 10-Q and 8-K. Our business, operating results or financial condition could be materially adversely affected by any of the following risks associated with any one of our businesses, as well as the other risks highlighted elsewhere in this document. The trading price of our common stock could decline due to any of these risks. Note that references to "our", "us", "we", "the Company", etc. used in each risk factor below refers to the business about which such risk factor is provided. Our business is subject to numerous risks as described in Item 1A. Risk Factors. Some of these risks include: We have limited resources and could find i

Risk Factors

Item 1A. Risk Factors

RISK FACTORS

RISK FACTORS Our business, operating results or financial condition could be materially adversely affected by any of the following risks associated with any one of our businesses, as well as the other risks highlighted elsewhere in this document. The trading price of our common stock could decline due to any of these risks. Note that references to "our", "us", "we", "the Company", etc. used in each risk factor below refers to the business about which such risk factor is provided. Risks Related to Our Financial Condition and Capital Needs We have limited resources and could find it difficult to raise additional capital. We may need to raise additional capital for operations and in order for stockholders to realize increased value on our securities. In the event the merger is consummated with Cyclo (the "Merger") and if the current Phase III trial for Trappsol Cyclo is successful, we may need to raise capital for the manufacturing, distribution and commercialization of Trappsol Cyclo . Given the current global economy and other factors, if we need to raise additional capital, there can be no assurance that we will be able to obtain the necessary funding on commercially reasonable terms in a timely fashion or at all. Failure to receive the funding could have a material adverse effect on our business, prospects, and financial condition. Our limited operating history makes it difficult to evaluate our business and prospects and may increase your investment risk. We have only a limited operating history upon which our business and prospects can be evaluated. We expect to encounter risks and difficulties frequently encountered by early-stage companies in the industries in which we operate. We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale medicine, or arrange for a third party to do so on our behalf, or conduct sales a

View Full Filing

View this 10-K/A filing on SEC EDGAR